Author Topic: Infection risks for patients w/MS treated w/Gilenya, Tysabri, Rituxan, injectable therapies  (Read 17 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8686
  • MS diagnosed 1980
  • Location: Pacific Northwest
From JAMA Neurology (February 2020; first published October 2019), "Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies." The researchers found that the beta interferons and Copaxone (glatiramer acetate) had the lowest infection rate, and rituximab had the highest.


http://bit.ly/2SmaGeN
« Last Edit: February 11, 2020, 08:07:03 pm by agate »
MS Speaks--online for 14 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Generic Copaxone (glatiramer acetate) 40mg 3 times/week since 12/16/20.

 

Related Topics